Craig Wheeler

Director

Craig A. Wheeler is the Chief Executive Officer of Headwaters Biotech Advisors, where he serves as an advisor to executives in the Biotech industry. Previously, Mr. Wheeler was President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he led the company through the launch of its first complex drug products, including the first generic versions of LOVENOX^® and once-daily COPAXONE^®. Prior to Momenta, Craig served as President, Chiron BioPharmaceuticals. Prior to joining Chiron, Craig was a senior member of The Boston Consulting Group’s health care practice and worked extensively in the health care sector with focus on pharma and biotech, particularly in regard to corporate and R&D strategy. Mr. Wheeler began his career at Merck & Company Inc. in the MSDRL research unit, where he served as a senior engineer in process development and at Hybritech as a financial analyst. In addition to Apellis, Mr. Wheeler currently serves on the Board of Directors of Amicus Therapeutics and previously served for nine years as the Chairman of the Board of Avanir Pharmaceuticals where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when its acquisition by Otsuka Pharmaceuticals. He also served as GPhA’s Chairman of the Board of Directors.

He holds a B.S. and an M.S. degree in chemical engineering from Cornell University, and an M.B.A. from the Wharton School of the University of Pennsylvania.